MedPath

sing radioactive iodide 125 in uveal melanoma

Phase 2
Conditions
veal melanoma.
Choroid
Registration Number
IRCT2016091929875N1
Lead Sponsor
Tehran University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
15
Inclusion Criteria

INCLUSION: All the patients with uveal melanoma that are not the candidates for ruthenium plaques and un-acception of the enucleation by the patient.

Exclusion: Unwillingness of the patient for continuing the study, pregnancy and nursing.

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Decrease in the thickness of tumor. Timepoint: At 4 months. Method of measurement: ultrasound and clinical examination.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath